AIM 7: THE PREVENTION OF NOCTURNAL HYPOGLYCEMIA IN TYPE 1 DIABETES

目标 7：预防 1 型糖尿病夜间低血糖

• 批准号: 7603329
• 负责人: PHILIP E. CRYER
• 金额: $ 0.47万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603329
• 关键词: Acarbose; Blood Glucose Self-Monitoring; Caring; Computer Retrieval of Information on Scientific Projects Database; Corn starch preparation; Diabetes Mellitus; End Point; Funding; Glucose Plasma Concentration; Glycosylated hemoglobin A; Goals; Grant; Hypoglycemia; Institution; Insulin-Dependent Diabetes Mellitus; Patients; Prevention; Reporting; Research; Research Personnel; Resources; Sampling; Source; Standards of Weights and Measures; Terbutaline; United States National Institutes of Health; diabetes management

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Iatrogenic hypoglycemia, particularly nocturnal hypoglycemia, is the limiting factor in the glycemic management of diabetes (Cryer et al, Diabetes Care 26:1902, 2003). Using the nocturnal nadir plasma glucose concentration as the primary endpoint, we plan to contrast three bedtime treatments that have been reported to be effective - terbutaline, cornstarch, acarbose - with the standard treatment, a conventional bedtime snack, and no treatment in patients with type 1 diabetes who are managing their diabetes aggressively as evidenced by a HbA1c of <=8.0% and a goal of morning self-monitoring of blood glucose values <=120mg/dL. Patients will be sampled during five overnight GCRC stays with the bedtime treatments given in random sequence.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 医源性低血糖，特别是夜间低血糖，是糖尿病血糖管理的限制因素(Cryer等人，Diabetes Care 26：1902，2003)。 使用夜间最低血糖浓度作为主要终点，我们计划将三种据报道有效的睡前治疗方法（特布他林、玉米淀粉、阿卡波糖）与标准治疗、传统睡前零食和不治疗的患者进行对比1 型糖尿病患者正在积极管理糖尿病，其 HbA1c <= 8.0% 和早晨自我监测血糖值 <= 120 mg/dL 的目标就是证据。 患者将在 5 次 GCRC 过夜期间进行采样，并按随机顺序进行睡前治疗。